Our research revealed 12 core targets potentially implicated in the therapeutic efficacy of QJSXP against ITP: CYP1B1, SYK, CCND1, AKT1, LYN, FYN, HIF1A, BLM, HPGD, MTOR, STAT3, and ADAM10. This evidence concerns the gene BLM and autoimmune thrombocytopenic purpura.